Dementia

This study is aimed at investigating the efficacy of a drug (JNJ-63733657) in delaying the progression of Alzheimer’s dementia by reducing the propagation of tau proteins. Participants will first attend a screen visit at the Royal Melbourne Hospital to ensure that they meet the criteria for the study. Once enrolled, they will be randomised in a 2:1 ratio to receive the drug or placebo.

Study duration is 4.5 years and will involve 36-38 visits to the Royal Melbourne Hospital throughout this time. Participants will receive the drug by way of intravenous infusion every 4 weeks.

Anticipated date that enrolment will close: December 2023

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Infectious Diseases

This is a clinical trial seeking to develop an mRNA vaccine for preventing Cytomegalovirus(CMV) infection. CMV infection is a common infection that can spread through saliva, blood, urine and breast milk. An infected healthy carrier normally has no symptoms, but symptoms may develop and include fever, muscles aches, moderate to severe fatigue, sore throat/swelling at back of throat, and/or swollen neck glands.

Infected pregnant women can infect their unborn child, causing congenital CMV infection. Infants with congenital CMV infection can have severe lifelong disabilities such as hearing loss, learning problems, vision abnormalities and potentially may be life-threatening, leading to death.

Anticipated date that enrolment will close: December 2022

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Psoriasis is a skin condition characterised by patches of skin that are typically red, itchy and scaly.

This study aims to understand the underlying mechanisms that trigger psoriasis and involves a one off-visit to clinics. The outcome of this project and knowledge gained will potentially support the development of new treatments for psoriasis and psoriatic arthritis.

Anticipated date that enrolment will close: Ongoing

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Basal cell carcinomas (BCC’s) are the most common skin cancer effecting Australians. Traditional first line treatment for BCC’s involves surgical excision but this can be quite invasive and suboptimal for certain tumours and patients, particularly when multiple tumours are present.

ASN-002 is a medication which contains interferon. Interferons Interferons are a group of signaling proteins made and released by host cells in response to the presence of several viruses. Intra-tumoural injections of interferons have been shown to be an effective treatment for non-melanoma skin cancers.

The aim of the Ascend study is to assess the safety and efficacy of ASN-002 combined with a hedgehog pathway inhibitor (Vismodegib) in the treatment of multiple low risk basal cell carcinomas in sporadic or basal cell naevus syndrome patients.

Anticipate date that enrolment will close: Ongoing

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Bullous pemphigoid (BP) is a rare, autoimmune skin condition characterised by blistering and itch. Many patients who have BP require treatment with topical steroids whilst others may require tablets, injections or infusions.

The investigational drug for this study is called benralizumab and given as an injection into the skin.

The purpose of this research project is to measure how safe and effective this medication is in treating participants with BP. Prior research studies in humans have shown that this medication may help regulate the immune system that is responsible for the signs and symptoms of BP and help achieve disease improvement.

Anticipated date that enrolment will close: Ongoing

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Lupus is an autoimmune condition that causes the body’s immune system to attack its own cells which in turn causes inflammation and tissue damage.

This trial investigates the effectiveness and safety of a drug called Enpatoran. Enpatoran is an oral medication designed to block specific cell pathways that cause the immune system to recognise the body as foreign and attack. In this trial, you will enter one of four arms. Three of these arms you will receive a varying dose of the trial medication and one of these arms will be a placebo (sugar tablet).

The trial is over 33 weeks with monthly visits to the Royal Melbourne Hospital's Clinical Trials Centre.

Anticipated date that enrolment will close: Ongoing

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Coeliac Disease

The only strategy to treat coeliac disease is a rigorous gluten-free diet. This research project is testing a potential new drug treatment for coeliac disease called IMU-856.

IMU-856 works by blocking a protein found in the gut that may strengthen the delicate gut lining and prevent damage caused by gluten. This could potentially lead to disappearance of symptoms of disease, promote healing of the intestinal lining, induce symptom relief, and improve quality of life for people with coeliac disease.

This is a randomised controlled study that will compare the active drug to a placebo in people with coeliac disease.

Anticipated date that enrolment will close: Ongoing

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Mental Health

This research project is testing a potential new treatment called Cannabidiol (CBD) for helping people with symptoms that might indicate risk of a psychotic disorder (UHR symptoms). CBD is a non-psychoactive treatment, meaning it does not you a ‘high’.

UHR symptoms vary for individuals, but can include feeling low in mood, feeling paranoid or seeing or hearing things that they know aren’t there. Some people might worry their thoughts are being heard, may not feel right in themselves, or have more difficulty than usual coping with work, school or relationships.

Anticipated date that enrolment will close: October 2025

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4